Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project
Scope
Scope 
Define a set of best practices for data transparency and create a Good Transparency Practices guidance. The best practices will aim to ensure anonymised data is compliant with the legal requirements
,
as defined by
regulators
Regulators, as well as
preserving
preserves as much data utility as possible. If possible,
regulators
Regulators such as the European Medicines Agency (EMA) and Health Canada will be consulted to ensure that the guidance created by the
Working Group
working group reflects their current standards. The planned document will have a similar format
to
as the Good Clinical Practices guidance created by the International Conference on Harmonisation (ICH). The Good Transparency Practices document will include: an introduction, a glossary of terms, a set of principles, and subsections dedicated to different parties involved in the anonymisation process (such as the trial sponsor and the entity performing the anonymisation)
,
describing their responsibilities and providing guidance. Additional sections may be added as needed.
 
   


Project
Problem Statement 
Transparency initiatives allow public scrutiny and research in the application of new knowledge based on clinical data. Current GxP guidelines do not apply to transparency as it represents a different flow of data in which anonymisation is carried out on a copy of the regulated data.


Project
Problem Impact
Good Transparency Practices (GTP) would provide a means to achieving accountability and traceability while providing reasonable assurance that privacy requirements are being upheld.



Project LeadsEmail

Lauren Hepburn (, ICON

lauren.hepburn@iconplc.com

Abby McDonell, Privacy Analytics)

lhepburn@privacyamcdonell@privacy-analytics.com

Paula Rowley (PHUSE Project Assistant)paula@phuse.global 
Objectives & Deliverables Timelines
Good Transparency Practices guidance documentQ32022

Lauren White, PHUSE Senior Project Coordinator 

lauren@phuse.global


Status
colourBlue
titleCurrent Status
Q12022

  • Group are completing current background research and organising notes to prepare for writing the GTP guidance.
  • Detailed outline presented at PHUSE winter conference.
  • Successfully solicited involvement from the EMA and Health Canada.
  • Group are beginning the first draft of GTP guidance.

Q1 2024

  • Publication of White Paper
  • Project close 



Astrazeneca
Objectives & Deliverables Timelines
Good Transparency Practices guidance documentQ2 2023
Project MembersOrganisation
Abhinav SrivastvaExelixis
Andre MolgatHealth Canada 
Benjamin C ShimEli Lilly
Brenda TiffinClaritidox
Cara CamporaBeigene
Devaki ThavarajahIndustry
Dhiraj DabhiEli Lilly
Mahesh SwaminathanBristol Myers Squibb
Manohara Basoor HalasiddappaAlgok Bio
Mekhala AcharyaTakeda
Sanjay Bagani Xogene 
Sarah BalayPrivacy Analytics
Sharon NiedeckenPfizer
Shannon LefaivreRoche
Shweta SrivastavaXogene 
Sophia ZilberPfizer
Rama Empati